🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareNovo Nordisk vs Eli Lilly — the GLP-1 market landscape in 2026 Page 3

Novo Nordisk vs Eli Lilly — the GLP-1 market landscape in 2026

anders_CPH Thu, Mar 19, 2026 at 1:00 PM 22 replies 1,194 viewsPage 3 of 5
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
Mar 22, 2026 at 2:06 AM#11
Dr.NephBHM_UK said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

That is correct as far as it goes, and here is where it stops going. Yes, and the corollary is less popular: if the reasoning holds, it also holds where it produces an answer we do not like.

4 2kim_atl_prep, sarah_TO, wendy_avl and 1 other
Reply Quote Save Share Report
sarah_nash92
Member
712
3,123
Jun 2024
Nashville, TN
Mar 22, 2026 at 1:45 PM#12
Dr.AddMedPHL said:
Dr.RaviCardio said: ...regarding the trial evidence...

Genuinely useful, thank you. I had the facts and not the framework. Printing the relevant bit and taking it with me.

5 3JakeSmashed95, NauseaFreeNow, SteveThurs and 2 others
Reply Quote Save Share Report
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Mar 23, 2026 at 1:23 AM#13
Dr.NephBHM_UK said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

This is where I part company with the consensus forming above. Pushing back on the anecdote-stacking. Twenty people reporting the same thing is twenty samples from the same self-selected pool, not twenty independent confirmations.

6 4jennifer_SEA, tyler_CSCS, VanRx_Mike and 3 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Mar 23, 2026 at 1:01 PM#14

Adding the numbers, since they settle part of this. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

7 5Dr.PulmRoch, maya_sedona, stefan_berlin and 4 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Mar 24, 2026 at 12:39 AM#15

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Tagging this one for the weekly digest.

Last edited: Mar 24, 2026 at 4:39 AM
8 6PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 5 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register